Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
CA 2331258 C · Owner: Uniformed Services University Of The Health Sciences · Inventors: Lees, Andrew; Mond, James J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides vaccine adjuvants comprising the Epstein Barr Virus glycoprotein 350/220 or naturally occurring variants thereof a , fusion , protein comprising EBV Gp350/220 sequence which binds to the CR2 receptor or , a , synthetically-derived fragment of Gp350/220 which retains the ability to bind to the , CR2 receptor. The present invention further provides immunostimulatory compositions comprising an EBV Gp350/220 adjuvant sequence that binds the CR2 complex and at least one antigen of interest other than Gp350/220. Coadministration , of the adjuvant with an antigen of interest other than an antigen , comprising EBV 350/220 sequence enhances the immunogenicity of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 10, 1999 and granted September 20, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 10, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 10, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.